Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-1826 injection in combination with other antitumor therapies in advanced solid tumors
CTR20244344Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1826 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Feb 2025; status: active.
02
Drugs
SHR-1826
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20244344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244344.